Opdivo 2017 U.S. PROMOTIONAL AUDIT REPORT

Published July 2018 • 25 Pages

The 5 Key Questions Addressed by this Report:

• How many physicians were reached by Opdivo through reportable promotional activity in 2017 and how does this compare to its peer set in the Bladder Cancer, Head and Neck Cancer, Hepatocellular Carcinoma, Hodgkin Lymphoma, Melanoma, Non-Small Cell Lung Cancer, and Renal Cancer markets?
• What promotional mix was leveraged (e.g., sales rep detailing, physician education, and paid speaking) and what was the median spend on each type of activity?
• How does BMS’s depth of coverage vary within key specialties (e.g., Hematology/Oncology, Medical Oncology, Radiation Oncology, and Internal Medicine) and how does this compare to its peers and the overall set of rep-accessible physicians?
• How often are physicians receiving paid meals for Opdivo throughout the year (e.g., monthly, quarterly, annually)?
• Who were the most frequent meal recipients and top paid speakers for Opdivo in 2017?

Data Sources and Methodology:

• MDDetails leverages company-reported financial transaction data disclosed through CMS Open Payments. This data set captures all transfers of value (e.g., speaking fees, consulting fees, travel, education, and meals) made on behalf of a drug or device manufacturer to a physician. More than four years of longitudinal data is available – covering payments to more than 975,000 U.S. healthcare professionals.
• Over 33,900 paid interactions across 6,600 physicians made on behalf of Opdivo were carefully examined to support our analysis. In addition, interaction data from 33 peer products (e.g. Abraxane, Adcetris, Afinitor, Alecensa, Alimta, Alunbrig, Avastin, Bavencio, Cabometyx, Cotellic, Cyramza, Erbitux, Gilotrif, Imfinzi, Imlygic, Inlyta, Iressa, Keytruda, Lenvima, Mekinist, Nexavar, Proleukin, Stivarga, Sutent, Tafinlar, Tagrisso, Tarceva, Tecentriq, Torisel, Votrient, Xalkori, Zelboraf, and Zykadia ) was leveraged to provide benchmarking and market insights.